SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration

por Barat, Stephen, Borroto-Esoda, Katyna, Angulo, David
Publicado 2017

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins

por Borroto-Esoda, Katyna, Angulo, David A, Azie, Nkechi
Publicado 2020

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates

por Barat, Stephen, Angulo, David, Borroto-Esoda, Katyna, Ghannoum, Mahmoud
Publicado 2017

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis

por Sobel, Jack D., Borroto-Esoda, Katyna, Azie, Nkechi, Angulo, David
Publicado 2021

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis

por Borroto-Esoda, Katyna, Barat, Stephen, Angulo, David, Holden, Kirsty, Warn, Peter
Publicado 2017

672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia

por Barat, Stephen, Borroto-Esoda, Katyna, Ghannoum, Mahmoud, Berkow, Elizabeth, Angulo, David A
Publicado 2019

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model

por Borroto-Esoda, Katyna, Azie, Nkechi, Ashbaugh, Alan, Cushion, Melanie, Angulo, David A
Publicado 2020

1054. Activity of a Anti-staphylococcal Lysin, LSVT-1701: In vitro Susceptibility of Staphylococcus aureus and Coagulase-Negative Staphylococci (CoNS) Global Clinical Isolates (200...

por Huang, David, Sader, Helio S, Rhomberg, Paul R, Borroto-Esoda, Katyna, Gaukel, Eric
Publicado 2021

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies

por Scorneaux, Bernard, Angulo, David, Borroto-Esoda, Katyna, Ghannoum, Mahmoud, Peel, Michael, Wring, Stephen
Publicado 2017

1071. Efficacy of Anti-Staphylococcal Lysin, LSVT-1701, in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis (IE) Due to Methicillin-Resistant Staphyloc...

por Huang, David, Gaukel, Eric, Borroto-Esoda, Katyna, Xiong, Yan, Abdelhady, Wessam, Bayer, Arnold
Publicado 2021

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

por Gamal, Ahmed, Chu, Sherman, McCormick, Thomas S., Borroto-Esoda, Katyna, Angulo, David, Ghannoum, Mahmoud A.
Publicado 2021

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study

por Feng, Joy Y, Ly, John K, Myrick, Florence, Goodman, Derrick, White, Kirsten L, Svarovskaia, Evguenia S, Borroto-Esoda, Katyna, Miller, Michael D
Publicado 2009

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology a...

por Larkin, Emily, Hager, Christopher, Chandra, Jyotsna, Mukherjee, Pranab K., Retuerto, Mauricio, Salem, Iman, Long, Lisa, Isham, Nancy, Kovanda, Laura, Borroto-Esoda, Katyna, Wring, Steve, Angulo, David, Ghannoum, Mahmoud
Publicado 2017

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidias...

por Wring, Stephen A., Randolph, Ryan, Park, SeongHee, Abruzzo, George, Chen, Qing, Flattery, Amy, Garrett, Graig, Peel, Michael, Outcalt, Russell, Powell, Kendall, Trucksis, Michelle, Angulo, David, Borroto-Esoda, Katyna
Publicado 2017

Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NT...

por Watashi, Koichi, Sluder, Ann, Daito, Takuji, Matsunaga, Satoko, Ryo, Akihide, Nagamori, Shushi, Iwamoto, Masashi, Nakajima, Syo, Tsukuda, Senko, Borroto‐Esoda, Katyna, Sugiyama, Masaya, Tanaka, Yasuhito, Kanai, Yoshikatsu, Kusuhara, Hiroyuki, Mizokami, Masashi, Wakita, Takaji
Publicado 2014

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

por Schwebke, Jane R, Sobel, Ryan, Gersten, Janet K, Sussman, Steven A, Lederman, Samuel N, Jacobs, Mark A, Chappell, B Todd, Weinstein, David L, Moffett, Alfred H, Azie, Nkechi E, Angulo, David A, Harriott, Itzel A, Borroto-Esoda, Katyna, Ghannoum, Mahmoud A, Nyirjesy, Paul, Sobel, Jack D
Publicado 2021

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

por Quindós, Guillermo, Miranda-Cadena, Katherine, San-Millán, Rosario, Borroto-Esoda, Katyna, Cantón, Emilia, Linares-Sicilia, María José, Hamprecht, Axel, Montesinos, Isabel, Tortorano, Anna Maria, Prigitano, Anna, Vidal-García, Matxalen, Marcos-Arias, Cristina, Guridi, Andrea, Sanchez-Reus, Ferran, Machuca-Bárcena, Jesús, Rodríguez-Iglesias, Manuel Antonio, Martín-Mazuelos, Estrella, Castro-Méndez, Carmen, López-Soria, Leyre, Ruiz-Gaitán, Alba, Fernandez-Rivero, Marcelo, Lorenzo, Damaris, Capilla, Javier, Rezusta, Antonio, Pemán, Javier, Guarro, Josep, Pereira, Joana, Pais, Célia, Romeo, Orazio, Ezpeleta, Guillermo, Jauregizar, Nerea, Angulo, David, Eraso, Elena
Publicado 2022